Trials / Completed
CompletedNCT00747097
Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II study is to assess the efficacy of combined chemotherapy using gemcitabine and cetuximab for advanced cholangiocarcinoma, excluding gallbladder cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gemcitabine + cetuximab | gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2008-09-04
- Last updated
- 2011-02-10
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00747097. Inclusion in this directory is not an endorsement.